Likely you are right. I still hope that it's a real change.
But the fact remains, share price is stuck or even went down since 2 years, despite stellar results , cashflow and cash accumulation. Talk about missed opportunity cost for shareholders with all that cash
The other fact also remains, sun's huge acquisitions and investments (taros solid results and taros negative leverage helps sun lower it's leverage ratio aiding hesee acquisitions)
Indeed a surprising move that they say "ceo to solely focus on taro".
Remains to be seen if it is theatrics( Dec independent dir elections are due - isS or glass lewis may weigh in like they did last time?) or really genuine
Hoping for quarterly earnings call
Hoping for inorganic growth
Hoping for details on novexatin, timeline,study results, why previous study was another phase2a. Why it took 3 years,etc
.Let's get a highly professional and importantly a CEO who cares for ALL shares including independent shareholders. Also hoping maybe they are exploring merger strategies with other public companies and get ceo from the target company to lead taro. Maybe (speculating)